Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd demonstrates a positive financial outlook due to promising developments in their study that may enable Glioblastoma patients to start treatment 2-3 months earlier, potentially increasing revenue per patient by 20-30%. The company is expected to see accelerated growth in active patients, particularly in the United States and Germany, serving as key indicators for future revenue growth through 2026. Additionally, the anticipated incremental revenue from new markets over the next 12-18 months will further support the company's overall revenue and growth trajectory.

Bears say

NovoCure Ltd is projected to experience a significant decline in EBITDA as revenue growth is expected to take time to materialize, possibly delaying the financial recovery. Analysts estimate that the company may not reach breakeven levels for EBITDA until 2027, potentially indicating challenges in achieving profitability in the near term. This extended timeline for financial improvement raises concerns regarding the sustainability of the company's operations and its overall financial health.

Novocure (NVCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 7 analysts, Novocure (NVCR) has a Buy consensus rating as of Oct 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.